From targeted medications and clinical hypnosis to dietary changes and herbal supplements, European menopause experts examine which hormone-free treatments hold the strongest scientific evidence for symptom relief.

Consensus Statement: Non-hormonal management of menopause symptoms - the statement of the European Society of Gynecology. Image Credit: gbrstock / Shutterstock
In a recent consensus statement published in the journal Gynecological Endocrinology, an international expert panel from the European Society of Gynecology (ESG) reviewed evidence on non-hormonal interventions to manage menopausal symptoms in women with medical contraindications to, or who prefer not to use, menopausal hormone therapy (MHT).
The statement identifies targeted neurokinin receptor antagonists as the most effective available non-hormonal pharmacological treatments for vasomotor symptoms (VMS). Lifestyle modifications, psychological therapies, and targeted interventions for genitourinary symptoms offer further options for managing menopause.
Background
The statement cites an estimate that approximately 47 million women experience the menopausal transition annually. Up to 80% of women experiencing vasomotor symptoms rate them as moderate to severe. Other menopausal symptoms include sleep disturbances, mood fluctuations, and genitourinary syndrome of menopause (GSM; e.g., vaginal dryness, irritation, and urinary discomfort).
Systemic MHT remains the most effective treatment for VMS, but it is contraindicated or unsuitable in women with certain medical conditions, including a history of estrogen-sensitive malignancy, prior venous thromboembolism, or cardiovascular disease. Many women who are eligible for MHT also prefer non-hormonal approaches.
Historically, the limited availability of approved non-hormonal treatments has led to the off-label use of antidepressants for VMS, while many women also seek complementary and herbal therapies.
About the statement
The consensus statement aimed to provide evidence-based clinical recommendations by evaluating non-hormonal treatments for menopause, with a focus on treatment efficacy, safety, and suitability for individual women.
A multidisciplinary expert panel prepared the statement and conducted a two-stage literature search across PubMed, MEDLINE, Embase, and the Cochrane Database to identify and screen publications on non-hormonal therapies for menopause, including clinical guidelines, systematic reviews, meta-analyses, randomized controlled trials (RCTs), and other primary studies.
A single author screened and critically appraised the literature for each assigned topic, and the panel collectively reviewed the resulting narrative summaries until consensus was reached. The authors did not conduct a new meta-analysis.
Lifestyle approaches to menopause care
The panel’s literature review identified a healthy diet, regular physical activity, weight management, and sleep hygiene as the foundation of menopause care. Mediterranean-style diets may improve cardiometabolic health, while resistance training and adequate calcium and vitamin D intake support muscle and bone health.
Exercise alone shows variable effects on hot flash frequency but consistently improves sleep quality, psychological well-being, and body composition.
New medications for hot flashes and night sweats
Among pharmacological alternatives to MHT, neurokinin receptor antagonists offer the strongest evidence of efficacy for treating patients experiencing vasomotor symptoms (VMS; e.g., hot flashes and night sweats). These medications target neural pathways involved in temperature regulation. No direct comparative trials with MHT have been conducted.
Clinical trials showed that fezolinetant, a selective neurokinin-3 receptor (NK3R) antagonist, reduced participants’ VMS frequency by approximately 63% after 12 weeks (compared with 40% for placebo) and maintained its efficacy over 52 weeks.
Elinzanetant, a dual neurokinin-1 receptor (NK1R) and NK3R antagonist, reduced VMS frequency by 65% to 67% in two phase 3 trials, compared with 42% to 46% in their respective placebo groups. The medication also reduced sleep disturbances, with evidence suggesting that some sleep benefits occur independently of VMS relief.
An indirect comparison suggested that the two medications offer similar relief from VMS, with potentially greater sleep benefits from elinzanetant.
Elinzanetant also reduced the frequency and severity of VMS in women receiving endocrine therapy for breast cancer, with benefits sustained over 52 weeks. Safety data for fezolinetant in women with a history of cancer remain limited.
Both agents require liver function testing before treatment and monitoring during use. Rare but serious drug-induced liver injury has been reported with fezolinetant, while clinical trials of elinzanetant have identified occasional increases in liver enzymes. Monitoring requirements vary by country.
Repurposed medications
Among repurposed medications, paroxetine remains the sole selective serotonin reuptake inhibitor (SSRI) approved by the United States Food and Drug Administration (FDA) for hot flashes.
Serotonin-norepinephrine reuptake inhibitors (SNRIs) such as venlafaxine and desvenlafaxine are preferred options for breast cancer survivors taking tamoxifen because they are less likely to interfere with its therapeutic activity.
Clinical trials of gabapentinoids, particularly gabapentin and pregabalin, have shown that these nerve pain medications can reduce VMS. Other repurposed medications, including clonidine and oxybutynin, may also relieve symptoms, but their efficacy and tolerability vary.
Psychological and complementary therapies
Among non-pharmacological treatments, cognitive behavioral therapy (CBT) can reduce the perceived intensity of hot flashes and associated distress, while clinical hypnosis can also reduce their frequency.
For example, a randomized controlled trial involving 187 women found that hypnosis reduced self-reported hot flash frequency by 74% and objectively measured hot flashes by 57%, while also improving sleep quality.
Mindfulness and yoga may help reduce menopausal symptom burden and improve psychological well-being, though evidence strength varies.
Selected standardized preparations of black cohosh (Cimicifuga racemosa), purified pollen extracts, and S-equol have demonstrated potential benefits, while evidence supporting soy isoflavones is modest and inconsistent, with more favorable findings in postmenopausal than perimenopausal women.
High-dose isoflavone supplements warrant caution in breast cancer survivors, while moderate dietary soy consumption is generally considered safe in this population.
Managing genitourinary symptoms
For mild to moderate GSM, the panel recommends vaginal moisturizers and lubricants as first-line non-hormonal treatments. Hyaluronic acid preparations can relieve vaginal symptoms, while pelvic floor muscle training may improve urinary continence and sexual function.
Local non-hormonal treatments generally provide symptomatic relief without reversing the underlying tissue atrophy associated with estrogen deficiency.
A meta-analysis of seven sham-controlled trials (401 participants) found no significant benefit of vaginal laser therapy over sham treatment. The panel advises against clinical use outside research settings because evidence of efficacy is insufficient and safety concerns remain unresolved.
Conclusions
The ESG concludes that individualized, multidisciplinary care that combines lifestyle medicine with behavioral strategies and selected non-hormonal drugs can improve symptoms and quality of life during menopause.
Treatment selection should reflect each woman's symptoms, medical contraindications, potential adverse effects, and personal preferences. Further research is needed to clarify the benefits and long-term safety of available treatments.
The authors reported no funding for the consensus statement, but several disclosed professional or financial relationships with pharmaceutical companies, including Astellas and Bayer.
Source:
Journal reference: